Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-08-05 Purchase |
2022-08-09 4:48 pm |
LEXICON PHARMACEUTICALS INC. | LXRX | Invus US Partners LLC Ulys L.L.C. DEBBANE RAYMOND Director 10% Owner |
147,390 | $2.5 | $368,475 | 5,782,749 (Indirect Direct) |
View |
| 2022-08-05 Purchase |
2022-08-09 4:46 pm |
LEXICON PHARMACEUTICALS INC. | LXRX | Artal International S.C.A. Wittouck Amaury Artal International Management S.A. Artal Group S.A. Westend S.A. Stichting Administratiekantoor Westend Invus Public Equities L.P. Invus L.P. Invus Public Equities Advisors LLC Invus Advisors L.L.C. Director 10% Owner |
2,426,070 | $2.5 | $6,065,175 | 89,778,234 (Indirect) |
View |
| 2022-08-01 Purchase |
2022-08-01 4:15 pm |
LEXICON PHARMACEUTICALS INC. | LXRX | Artal International S.C.A. Wittouck Amaury Artal International Management S.A. Artal Group S.A. Westend S.A. Stichting Administratiekantoor Westend Invus Public Equities L.P. Invus L.P. Invus Public Equities Advisors LLC Invus Advisors L.L.C. Director 10% Owner |
16,173,800 | $2.5 | $40,434,500 | 87,352,164 (Indirect) |
View |
| 2022-08-01 Purchase |
2022-08-01 4:15 pm |
LEXICON PHARMACEUTICALS INC. | LXRX | Invus US Partners LLC Ulys L.L.C. DEBBANE RAYMOND Director 10% Owner |
982,600 | $2.5 | $2,456,500 | 5,635,359 (Indirect Direct) |
View |
| 2022-08-01 Purchase |
2022-08-01 4:13 pm |
LEXICON PHARMACEUTICALS INC. | LXRX | DEBBANE RAYMOND Director |
982,600 | $2.5 | $2,456,500 | 5,635,359 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-09 Option Award |
2023-02-13 4:59 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Granowitz Craig B SVP, Chief Medical Officer |
429,480 | $0 | 429,480 (Direct) |
View |
| 2023-02-09 Option Award |
2023-02-13 4:58 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Crum Brian T SVP, General Counsel & Secr. |
401,470 | $0 | 401,470 (Direct) |
View |
| 2023-02-09 Option Award |
2023-02-13 4:56 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | WADE JEFFREY L President and CFO |
589,370 | $0 | 589,370 (Direct) |
View |
| 2023-02-09 Option Award |
2023-02-13 4:55 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | COATS LONNEL Chief Executive Officer |
1,444,590 | $0 | 1,444,590 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:18 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | Swain Judith L Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:17 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | SOBECKI CHRISTOPHER J Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:16 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | NIES ALAN S Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:15 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | Palantoni Frank Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:14 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | LEFKOWITZ ROBERT J MD Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:14 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | DEBBANE RAYMOND Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:13 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | BARKER SAM L Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-05-21 Option Award |
2022-05-23 4:12 pm |
N/A 2032-05-21 |
LEXICON PHARMACEUTICALS INC. | LXRX | Amouyal Philippe Director |
23,704 | $0 | 23,704 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:22 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Swain Judith L Director |
4,024 | $0 | 31,030 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:18 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | SOBECKI CHRISTOPHER J Director |
4,024 | $0 | 149,721 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:17 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Palantoni Frank Director |
4,024 | $0 | 31,030 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:16 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | NIES ALAN S Director |
4,024 | $0 | 31,744 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:15 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | LEFKOWITZ ROBERT J MD Director |
4,024 | $0 | 31,030 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:14 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | DEBBANE RAYMOND Director |
4,024 | $0 | 4,652,759 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:12 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | BARKER SAM L Director |
4,024 | $0 | 70,315 (Direct) |
View |
| 2022-04-30 Exercise |
2022-05-02 4:11 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Amouyal Philippe Director |
4,024 | $0 | 31,030 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:18 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Alexander Kristen VP, Finance and Accounting |
11,300 | $0 | 27,763 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:18 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Alexander Kristen VP, Finance and Accounting |
3,337 | $2.85 | 27,763 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:17 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Seth Kiernan VP, Chief Commercial Officer |
30,128 | $0 | 47,273 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:17 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Seth Kiernan VP, Chief Commercial Officer |
8,261 | $2.85 | 47,273 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:16 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | MAIN ALAN J EVP, Innov & Chem Sciences |
54,650 | $0 | 216,842 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:16 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | MAIN ALAN J EVP, Innov & Chem Sciences |
19,756 | $2.85 | 216,842 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:15 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Kassler-Taub Kenneth B. SVP, Regulatory & QA |
36,628 | $0 | 118,273 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:15 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Kassler-Taub Kenneth B. SVP, Regulatory & QA |
13,241 | $2.85 | 118,273 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:13 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Crum Brian T SVP, General Counsel & Secr. |
40,880 | $0 | 137,988 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:13 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | Crum Brian T SVP, General Counsel & Secr. |
15,059 | $2.85 | 137,988 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:12 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | WADE JEFFREY L President and CFO |
66,933 | $0 | 246,500 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:12 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | WADE JEFFREY L President and CFO |
25,773 | $2.85 | 246,500 (Direct) |
View |
| 2022-02-28 Exercise |
2022-02-28 7:11 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | COATS LONNEL Chief Executive Officer |
197,343 | $0 | 737,300 (Direct) |
View |
| 2022-02-28 Tax Withholding |
2022-02-28 7:11 pm |
N/A N/A |
LEXICON PHARMACEUTICALS INC. | LXRX | COATS LONNEL Chief Executive Officer |
48,053 | $2.85 | 737,300 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:11 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | McDermott Wendy VP, Human Resources |
227,330 | $0 | 227,330 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:10 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | MAIN ALAN J EVP, Innov & Chem Sciences |
307,990 | $0 | 307,990 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:09 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | Seth Kiernan VP, Chief Commercial Officer |
275,560 | $0 | 275,560 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:08 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | WADE JEFFREY L President and CFO |
447,290 | $0 | 447,290 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:06 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | Kassler-Taub Kenneth B. SVP, Regulatory & QA |
330,680 | $0 | 330,680 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:05 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | COATS LONNEL Chief Executive Officer |
1,096,370 | $0 | 1,096,370 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:04 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | Granowitz Craig B SVP, Chief Medical Officer |
335,000 | $0 | 335,000 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 4:03 pm |
N/A 2032-02-10 |
LEXICON PHARMACEUTICALS INC. | LXRX | Crum Brian T SVP, General Counsel & Secr. |
313,160 | $0 | 313,160 (Direct) |
View |